$SNPS

DE GEUS AART sold $21.4M of SNPS

DE GEUS AART (EXECUTIVE CHAIR) sold 49,641 shares of SYNOPSYS INC (SNPS) at an average of $430.68 ($419.44–$441.76, $21.38M total) across 2 trades over 2026-08-31 to 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DE GEUS AART
Published Sep 2, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 7:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNPS
Bearish
medium confidence
Mentioned
$SNPS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNPSBearishMed
01

Why it matters

The disclosed sale could trigger short‑term selling pressure, but the pre‑arranged nature may limit its signaling value.

02

Market read

Primary insider sell provides fresh material information for traders evaluating SNPS.

03

What to watch

Potential tax planning or diversification motives could mitigate negative interpretation.

Relevance 6/10Novelty 7/10Timing: filing released after market close on 2026‑09‑02

Background

Form 4 filings disclose insider transactions; a sale of this size by the executive chair is noteworthy.

Company-level read

Ticker impact

$SNPSBearishMedium confidence
Context

Executive Chair Aart de Geus sold $21.4M of Synopsys shares via a 10b5‑1 plan, reducing his stake to 120,443 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $21M sale by the company's top executive is material and disclosed first via Form 4; markets often react to sizable insider disposals.

Market effects

May raise questions about Synopsys' growth outlook within the EDA sector.

Limited to U.S. tech equities; no broader regional effect.

Minimal global impact beyond Synopsys investors.

Counterpoint

The sale is pre‑arranged under a 10b5‑1 plan and may not reflect current sentiment.

Key entities

  • Synopsys Inc.

    U.S. listed provider of electronic design automation software (ticker SNPS).

  • Aart de Geus

    Executive Chair of Synopsys, filing a $21.4M share sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNPSMed

Why Should You Think About Synopsys Differently Now?

Synopsys (SNPS) trades at 80.8x P/E, focusing on AI-driven chip design and Ansys. Its IP business, which underperformed due to export restrictions and customer challenges, returned to growth in Q3 2026. Ansys revenue was 1.5x Design IP's revenue in the same quarter. Management highlights a shift to a licensing-plus-royalties model, with a $1B+ deal with Amazon.

$SNPSMed

S&P lifts Synopsys to ’BBB+’ as chip-design leader capitalizes on AI demand

S&P Global Ratings upgraded Synopsys Inc's credit rating to 'BBB+' from 'BBB', citing strong long-term growth prospects driven by AI demand. The company expects mid-teens revenue growth through 2029 and improved profitability, with 2029 EBITDA margin projected at 49%. Synopsys is also accelerating cost synergies from its Ansys acquisition and expanding commercial traction, including a $1B+ contract with Amazon.

$AMZNMedAI 8/10

Amazon and Synopsys seal $1bn technology partnership

Amazon and Synopsys have signed a $1 billion deal to accelerate Amazon's custom silicon innovation and advance AI products and cloud infrastructure. The multi-year agreement builds on 15 years of collaboration, with Synopsys providing application-optimized silicon IP. Amazon's Peter DeSantis highlighted the impact of custom silicon on AWS, while Synopsys' Sassine Ghazi emphasized the partnership's role in shaping AI-native engineering.

$SNPSMed

Morgan Stanley Thinks Synopsys’ AI Story Isn’t Priced In

Morgan Stanley raised its price target for Synopsys to $574 from $500, forecasting fiscal 2027 EPS of $19.12. The firm believes Synopsys' AI story isn't fully priced in, but a re-rating depends on execution and proof of usage revenue growth. Investors will watch for metrics like customer retention and contracted backlog.